Following this report, other groups screened their datasets for FGFR-TACC fusion genes: Di Stefano et al. found 17 of 584 glioblastomas (2.9%) and 3 out of 221 lower grade gliomas (3.5%) to be positive for FGFR3-TACC3 fusion. This evidence concerns the gene TACC3 and central nervous system cancer.